Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$330.96M+174%-$282.85M-278%-$179.95M-635%-$447.51M-1,339%
$10.59M+6.2%$5.25M-49.8%$18.45M+88.2%$10.84M+24.3%$9.98M+14.1%
$29.4M-29.0%$30.02M-39.6%$14.93M-65.6%$37.03M-26.7%$41.43M+1.8%
-$202.68M+65.3%-$14.59M+79.4%-$583.44M-141%
$2.08M-95.2%$3.59M-90.6%$22.93M-38.5%$31.8M+9.0%$43.65M+34.5%
-$134.39M+53.8%$96.21M-87.4%-$291.18M-233%
$250M$0
$250M$35.09M$0
$241K-98.1%-$39.21M-180%-$117.79M-956%-$23.82M-160%$12.47M-43.7%
-$336.83M+60.9%-$862.14M-75,527%
-$204.76M+67.3%-$37.52M+65.2%-$627.09M-128%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Sarepta Therapeutics, Inc. generate?
Sarepta Therapeutics, Inc. (SRPT) generated -$871.4M in operating cash flow over the trailing twelve months.
What is Sarepta Therapeutics, Inc.'s free cash flow?
After $60.4M of capital expenditures, Sarepta Therapeutics, Inc.'s free cash flow was -$977.3M over the trailing twelve months, down 92.8% year over year.
Where does Sarepta Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.